Access cutting-edge systemic sclerosis treatment through this phase 3 clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Birmingham location
Preparing your pre-screening questions…
Access systemic sclerosis specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related systemic sclerosis treatment provided free
Check if you qualify for this systemic sclerosis clinical trial in Birmingham, AL
No-Cost Study Care
Local to Birmingham
Convenient for AL residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Nerandomilast is being developed to help people with systemic sclerosis by potentially improving symptoms and slowing disease progression. This study is open to adults who are at least 18 years old and have systemic sclerosis (SSc). People can join the study if they have limited or diffuse cutaneous SSc with disease onset within 7 years of the first non-Raynaud's symptom. The purpose of this study is to find out whether a medicine called nerandomilast helps people with systemic sclerosis. This study also aims to find out how well nerandomilast is tolerated in people with systemic sclerosis. Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take the tablets twice a day. Participants are in the study for 1 to about 4 years. During this time, they visit the study site regularly and get phone calls from the site staff. During study visits participants regularly have blood samples taken and doctors check changes in skin thickening, lung function, and internal organs, overall health and the safety and tolerability of study treatment in people with SSc. The results are compared between the groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Sponsor: Boehringer Ingelheim
Yes, this clinical trial (NCT07497087) has an active research site in Birmingham, AL that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for systemic sclerosis treatment options in Birmingham, AL, this clinical trial (NCT07497087) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced systemic sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all systemic sclerosis clinical trials near you to find additional studies recruiting in your area.
See all heart attack clinical trials recruiting in Birmingham — not just this study.
Browse Heart Attack Trials in Birmingham →